Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
31 studies found for:    " November 03, 2010":" December 03, 2010"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Download search resultsDownload the search results for:
" November 03, 2010":" December 03, 2010"[FIRST-RECEIVED-DATE]AND HIV[CONDITION] (31 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Completed Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects
Conditions: HIV;   HIV Infection
Intervention: Biological: SB-728-T
2 Completed A Randomized Controlled Trial of the Bruthas Project
Condition: HIV Infection
Interventions: Behavioral: Bruthas Project;   Behavioral: Standard HIV Testing and Counseling
3 Unknown  Improving Antiretroviral Medication Adherence Among HIV-infected Youth: Phase I
Condition: HIV Infection
Intervention:
4 Unknown  Impact of Raltegravir on the Viral Reservoirs
Condition: HIV Infection
Intervention:
5 Completed Study of Lopinavir/ Ritonavir and Lamivudine Versus Standard Therapy in Naïve HIV-1 Infected Subjects.
Condition: HIV Infection
Interventions: Drug: lopinavir/ritonavir plus one nucleoside;   Drug: lopinavir /ritonavir plus two nucleosides
6 Completed The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)
Condition: HIV Infections
Intervention: Drug: Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)
7 Withdrawn A Safety and Pharmacokinetic Study for Dapivirine and Maraviroc Gel in Belgium
Condition: HIV Infections
Interventions: Drug: Maraviroc/Dapivirine Gel;   Drug: Dapivirine Vaginal Gel;   Drug: Maraviroc Vaginal Gel;   Drug: Matching Placebo Gel
8 Completed Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Condition: HIV
Intervention:
9 Active, not recruiting Addition of Raltegravir to Established Antiretroviral Suppressive Therapy
Condition: HIV
Intervention: Drug: Raltegravir
10 Completed Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Populations Using Formula Feeding (PROMISE)
Condition: HIV
Interventions: Drug: Zidovudine (ZDV);   Drug: Nevirapine (NVP);   Drug: Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]);   Drug: Lamivudine-Zidovudine (3TC-ZDV);   Drug: Lopinavir-ritonavir (LPV-RTV)
11 Withdrawn A Multicentre Trial of Second-line Antiretroviral Treatment Strategies in African Adults Using Atazanavir or Lopinavir/Ritonavir
Condition: HIV
Interventions: Drug: Lopinavir;   Drug: Atazanavir
12 Completed The Influence of GINkGo Biloba on the Pharmacokinetics of the UGT Substrate raltEgraviR (GINGER)
Conditions: HIV Infections;   Depression;   Mild Cognitive Impairment
Interventions: Drug: raltegravir single dose;   Drug: ginkgo biloba multiple dose
13 Terminated Randomized Study on Multiple Cycles of Interleukin-7 in HIV Patients Immune Non-responders
Condition: HIV
Intervention: Drug: CYT107
14 Completed
Has Results
Addressing Psychosocial Needs and HIV Risk in Indian MSM
Conditions: HIV/STI Risk;   HIV/STI Incidence
Intervention: Behavioral: Behavioral intervention
15 Completed
Has Results
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF
Condition: HIV-1 Infection
Interventions: Drug: FTC/RPV/TDF;   Drug: PI;   Drug: RTV;   Drug: NRTIs
16 Completed
Has Results
Vitamin D in HIV-Infected Patients on HAART
Conditions: Vitamin D Deficiency;   HIV
Intervention: Dietary Supplement: Vitamin D
17 Unknown  Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3
Condition: HIV-1 Infection
Intervention: Drug: Maraviroc
18 Completed
Has Results
Will Having Alcohol Treatment Improve Functioning?
Conditions: HIV;   Alcoholism
Interventions: Drug: Naltrexone, 50mg, once per day for 4 months;   Other: Sugar pill, 50mg, once per day for 4 months
19 Completed IMPAACT P1073: Study of IRIS for Infants and Children Initiating HAART at Int'l Sites
Conditions: IRIS;   HIV
Intervention:
20 Withdrawn The Effect of Pregnancy on the PK of Isentress®: A Longitudinal Investigation in the Second and Third Trimesters
Conditions: HIV;   Pregnancy
Intervention: Other: Pharmacokinetics

   Previous Page Studies Shown (1-20) Next Page (21-31) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.